4D Molecular Therapeutics (FDMT) and The Competition Financial Contrast

4D Molecular Therapeutics (NASDAQ:FDMT) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare 4D Molecular Therapeutics to related companies based on the strength of its risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Valuation and Earnings

This table compares 4D Molecular Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
4D Molecular Therapeutics	$92.01 million	-$140.11 million	-4.74
4D Molecular Therapeutics Competitors	$741.60 million	$14.11 million	-15.43

4D Molecular Therapeutics’ rivals have higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for 4D Molecular Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1	0	10	0	2.82
4D Molecular Therapeutics Competitors	9839	15126	45469	1588	2.54

4D Molecular Therapeutics presently has a consensus price target of $30.22, indicating a potential upside of 142.53%. As a group, “Biotechnology” companies have a potential upside of 98.31%. Given 4D Molecular Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe 4D Molecular Therapeutics is more favorable than its rivals.

Profitability

This table compares 4D Molecular Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
4D Molecular Therapeutics Competitors	-12,346.73%	-197.60%	-30.56%

Volatility and Risk

4D Molecular Therapeutics has a beta of 2.92, indicating that its share price is 192% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics’ rivals have a beta of 1.10, indicating that their average share price is 10% more volatile than the S&P 500.

Summary

4D Molecular Therapeutics beats its rivals on 8 of the 13 factors compared.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.